Adia Med Kicks Off Recruitment Today for Innovative Autism Stem Cell Study

Winter Park, Florida--(Newsfile Corp. - January 13, 2026) - ADIA Nutrition Inc. (OTCQB: ADIA), today announced that its subsidiary, Adia Med of Winter Park, LLC., has officially begun the recruitment process for a groundbreaking clinical study evaluating the potential benefits of stem cell therapy in children with Autism Spectrum Disorder (ASD).

The 24-month randomized interventional study, officially titled "Adia MED of Winter Park LLC Autism Spectrum Disorder Research Study" and listed on ClinicalTrials.gov (NCT07304440), is being conducted at Adia Med's clinic in Winter Park, Florida.

Adia MED of Winter Park LLC Autism Spectrum Disorder Research Study: https://clinicaltrials.gov/study/NCT07304440

Adia Med ASD Study Recruiting Status

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10520/280212_adiaasd.jpg

ClinicalTrials.gov has provided receipt confirmation that the study is now in recruiting status, and it should appear publicly in recruiting status on the site within the next few days.

The trial aims to enroll approximately 100 children ages 3-12 with a confirmed ASD diagnosis. This study investigates whether combining AdiaVita-Adia Med's proprietary umbilical cord blood-derived stem cell and exosome product-with glutathione therapy provides greater improvement in autism symptoms compared to glutathione therapy alone. Participants will be randomly assigned to one of two groups for the initial three-month phase:

• One group will receive glutathione only.
• The other will receive glutathione plus monthly intravenous infusions of AdiaVita.

Success will be assessed over the full 24 months using the Autism Treatment Evaluation Checklist (ATEC), completed by parents as well as therapists or teachers. The primary outcome is the change in total ATEC scores at six months, with additional focus on safety, tolerability, quality of life, and overall well-being through regular clinic visits, physical exams, blood tests, and adverse event monitoring. After the initial phase, children in the glutathione-only group will have the opportunity to cross over and receive AdiaVita infusions at no additional cost.